https://de.marketscreener.com/kurs/aktie/CASI-PHARMACEUTICALS-INC-16699864/news/CASI-Pharmaceuticals-und-BioInvent-geben-die-Verabreichung-des-ersten-Patienten-in-der-klinischen-Ph-41722352/?utm_source=telegram&utm_medium=social&utm_campaign=share